Publication: Correlation of securin and Ki67 in invasive breast carcinoma
Authors
Mamdouh Talaat, Iman ; Akram Hamoudi, Rifat ; Mahmoud Yakout, Nada ; Youssef Oweiss, Nagwa ; Mohammed Omar, Abbas
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-18-071
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Aims. To identify the role of securin (PTTG)
as a prognostic marker in invasive breast carcinoma and
its possible relation to ki67 and to evaluate the use of
ImmunoRatio® as a tool for calculating ki67 and securin
labelling indices. Methods. Securin and ki67
immunohistochemical staining were performed on tissue
microarray sections representative of 118 patients
diagnosed with invasive breast carcinoma from 2005 to
2011. Assessment of immunohistochemical staining was
carried out using both visual counting and
ImmunoRatio®. The 118 cases were categorized into 2
groups according to their clinical outcome; the first
group (G1) (n=77) comprised patients who were diseasefree while the second group (G2) (n=41) included
patients who developed either recurrence and/or
metastasis at the end of 24 months follow-up duration.
Results. Both securin and ki67 labelling indices (LIs)
obtained by visual counting were significantly higher in
G2, while only securin LIs acquired by ImmunoRatio®
were significantly higher in G2. Securin assessment by
visual counting was the most accurate (AUC=0.775) in
identifying patients who will likely suffer from
recurrence and/or distant metastasis. Pearson correlation
showed r=0.638, p<0.001 for Ki67 and r=0.671, p<0.001
for securin. Linear regression analysis showed a
significant correlation between ki67 and securin,
B=1.75, p<0.001. Conclusion. The present results
suggest that securin may add to the prognostic value of
ki67 in highlighting intra-tumoural heterogeneity in
invasive breast carcinoma patients with poor clinical
outcome. In addition, the study showed that since
securin has a visual counting cutoff with more than 1%,
making it easier to use as a breast cancer biomarker in
conjunction with ki67 to predict the outcome of the
cases more accurately than using only ki67. However, a
multivariate analysis on a larger cohort of patients is
mandatory to test its potential prognostic value.
publication.page.subject
Citation
Histology and Histopathology, Vol.34, nº6, (2019)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/